Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.

about

Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints.

P2860

Q39084926-205A2803-0D8D-46E8-9F27-8F1AC361A041

P2860

Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38969036

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Targeted therapies: what they ...... iasis and psoriatic arthritis.

@en

type

Item

label

Targeted therapies: what they ...... iasis and psoriatic arthritis.

@en

prefLabel

Targeted therapies: what they ...... iasis and psoriatic arthritis.

@en

P1476

Targeted therapies: what they ...... iasis and psoriatic arthritis.

@en

P2093

Costantino Pitzalis

http://www.w3.org/2001/XMLSchema#string

Stephen Kelly

http://www.w3.org/2001/XMLSchema#string

Wang Sin Gina Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study

IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond

IL-17 and Th17 Cells

Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

P304

207-222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/1744666X.2017.1241710

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27690678

http://www.w3.org/2001/XMLSchema#string

P921

pathogenesis

Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.

about

P2860

P2860

Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921